查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1999430

带状疱疹疫苗市场：按疫苗类型、剂量、年龄层、分销管道和最终用户分類的全球市场预测 – 2026-2032 年

Shingles Vaccine Market by Vaccine Type, Dosage, Age Group, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，带状疱疹疫苗市场价值将达到 20.2 亿美元，到 2026 年将成长至 21.9 亿美元，到 2032 年将达到 36.6 亿美元，复合年增长率为 8.80%。

主要市场统计数据
基准年 2025 20.2亿美元
预计年份：2026年 21.9亿美元
预测年份：2032年 36.6亿美元
复合年增长率 (%) 8.80%

全面概述影响带状疱疹疫苗策略的临床、商业性和政策因素，以及这些因素对整个价值链相关人员的影响。

带状疱疹是由水痘-带状疱疹病毒重新运作引起的，由于其发病率老龄化增长而增加，且易引发严重的併发症，如带状疱疹后遗症神经痛，因此仍然是老年人群面临的一项重大公共卫生问题。儘管疫苗技术的进步已经改变了预防策略，但支付方环境和分销模式的变化正在影响疫苗的可及性和接种率。本执行摘要概述了正在重塑带状疱疹疫苗格局的最显着的临床、商业性和政策趋势，并重点阐述了这些趋势对研发、生产、分销和患者照护等各个环节相关人员的影响。

对带状疱疹疫苗的引进和采购方法进行详细说明，以及正在改变整个医疗保健生态系统中相关人员期望的多方面变革因素。

带状疱疹疫苗领域正经历一系列变革，其影响​​范围已超越产品性能，涵盖分销、支付方参与和患者期望等各个方面。包括改进的重组抗原平台和佐剂系统在内的技术进步，提高了疫苗的有效性标准并修订了临床指南，迫使医疗系统和临床医生重新评估成人免疫通讯协定。同时，低温运输物流和数位化分销管道的进步正在扩大疫苗的可及性，同时也对库存管理和供应商选择提出了新的考量。

对关税主导的贸易趋势如何重塑带状疱疹疫苗的供应链决策、采购弹性策略和商业合约方法进行详细分析。

关税和贸易措施等政策的调整可能会对整个医药供应链产生连锁反应，相关人员被敦促评估自身营运的韧性，以应对预计在2025年实施的关税措施。製造商和经销商正在重新审视其关键原料、佐剂和管瓶的筹资策略，以降低进口成本上升和海关延误风险。为此，采购团队正在努力实现供应商多元化，认证区域性製造商，并谈判包含价格保护条款的长期合同，以确保供应的连续性。

策略洞察，阐明疫苗类型、年龄层、最终用户、分销管道和剂型如何相互作用并影响疫苗的引入和交付。

将带状疱疹疫苗市场细分，可以揭示产品、人口统计特征、医疗机构、分销模式和接种方法如何相互作用，从而影响疫苗的引入管道和服务提供模式。根据疫苗类型，此市场环境可分为重组带状疱疹疫苗和减毒活疫苗。重组疫苗在老年族群中已展现出较高的疗效，并影响了临床指引的製定；而减毒活病毒疫苗在特定临床情况下仍然效用。决策者在评估产品系列，除了考虑影响下游物流的储存和处理要求外，还必须考虑这些疗效和安全性方面的差异。

跨区域比较观点揭示了支付方趋势、基础设施和人口压力如何推动世界各地不同的部署和存取策略。

区域趋势正在影响带状疱疹疫苗价值链中相关人员的实际情况和策略挑战。在美洲，公共和私人支付方越来越重视展现成人免疫接种计划的价值，这加速了对社区推广和综合护理路径的投资，旨在提高老年人的疫苗接种率。主要市场的医疗保健系统正在利用电子健康记录和免疫接种登记系统来缩小医疗服务差距，而分销网络则优先考虑冷藏物流和与连锁药局的合作，以最大限度地提高疫苗的可及性。

全面的竞争情报突显了临床证据、营运韧性和策略伙伴关係如何定义带状疱疹疫苗市场的领导地位。

如今，带状疱疹疫苗领域的竞争优势不仅取决于临床差异化，还取决于一系列综合能力，包括供应链敏捷性、证据产生和多通路商业性营运能力。主要企业正在投资核准后研究和真实世界数据（REW）项目，以证明疫苗的长期疗效，并为与保险公司和医疗系统进行合约谈判提供支援。同时，低温运输物流、灌装和包装能力的卓越营运以及供应商多元化已成为降低关税和贸易相关风险的策略重点。

透过协调证据产生、供应弹性、全通路分销和相关人员合作，加速疫苗取得和接种率的实用建议。

业界领导者应优先采取一系列切实可行且影响深远的措施，以应对带状疱疹疫苗领域瞬息万变的局面，并掌握新兴机会。首先，各机构需要投资产生细緻的真实世界数据（REW），以展现不同年龄组和临床亚组的疫苗疗效对比，从而在与支付方谈判以及与临床医生探讨疫苗采纳问题时，提出更具提案的价值主张。其次，他们可以透过供应商多元化、建立区域製造伙伴关係关係以及检验的低温运输紧急应变计划来增强供应链韧性，从而降低贸易和关税波动带来的风险。

我们采用透明的混合方法研究途径，结合专家访谈、监管资讯和情境分析，为决策者提供可操作的、检验的见解。

本分析基于混合调查方法，旨在整合关键相关人员的见解，并结合严谨的二手研究资料进行整合和检验。核心调查方法结合了对临床专家、采购经理和分销合作伙伴的深入访谈，以及从公开的监管公告、临床文献和政策声明中资料提取。访谈在不同的医疗机构和地区进行，旨在了解影响疫苗供应的运作差异，并全面检验有关疫苗部署障碍和驱动因素的新主题。

我们将透过简洁地整合与临床进展、供应韧性、细微的细分差异和区域差异相关的策略挑战，来实现疫苗取得目标。

总之，带状疱疹疫苗市场正处于转折点，技术进步、人口结构变化和采购模式的演变相互交织，为整个价值链上的相关人员带来了挑战和机会。重组疫苗平台和改进的物流解决方案提高了人们对临床疗效的期望，并拓展了更广泛的成人免疫策略的可能性；同时，关税和贸易趋势要求供应链结构更具韧性，商业模式更具适应性。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：带状疱疹疫苗市场：依疫苗类型划分

  • 重组疫苗
  • 减毒活病毒疫苗

第九章：带状疱疹疫苗市场：依剂量划分

  • 多次给药
  • 单一剂量

第十章：带状疱疹疫苗市场：依年龄组别划分

  • 50-59岁
  • 60-69岁
  • 70岁以上

第十一章：带状疱疹疫苗市场：按分销管道划分

  • 医院药房
  • 网路药房
    • 数位药房
    • 电子商务平台
  • 零售药房
    • 连锁药局
    • 独立经营药房

第十二章：带状疱疹疫苗市场：依最终用户划分

  • 诊所
    • 当地诊所
    • 私人诊所
  • 医院
    • 综合医院
    • 专科医院

第十三章：带状疱疹疫苗市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：带状疱疹疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：带状疱疹疫苗市场：按国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国带状疱疹疫苗市场

第十七章：中国带状疱疹疫苗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AIM Vaccine Co., Ltd.
  • Bavarian Nordic A/S
  • Beijing Institute of Biological Products Co., Ltd.
  • Bharat BIoTech International Limited
  • Biological E. Limited
  • CanSino Biologics Inc.
  • CanSinoBIO
  • Changchun BCHT BIoTechnology Co., Ltd.
  • Chengdu Institute of Biological Products Co., Ltd.
  • Daiichi Sankyo Company, Limited
  • Dynavax Technologies Corporation
  • GeneOne Life Science
  • GlaxoSmithKline plc
  • Green Cross Corporation
  • Jiangsu Recbio Technology Co., Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Life Sciences Co., Ltd.
  • SK chemicals
  • Vaccitech plc
  • Valneva SE
  • Vaxart, Inc.
  • Yuxi Walvax BIoTechnology Co., Ltd.
Product Code: MRR-563BF1FCEEC2

The Shingles Vaccine Market was valued at USD 2.02 billion in 2025 and is projected to grow to USD 2.19 billion in 2026, with a CAGR of 8.80%, reaching USD 3.66 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.02 billion
Estimated Year [2026] USD 2.19 billion
Forecast Year [2032] USD 3.66 billion
CAGR (%) 8.80%

Comprehensive orientation to the clinical, commercial, and policy forces shaping shingles vaccine strategy with implications for stakeholders across the value chain

Shingles, caused by reactivation of varicella-zoster virus, remains a significant public health concern for older adults due to rising incidence with advancing age and the debilitating complications associated with postherpetic neuralgia. Advances in vaccine technology have reshaped prevention strategies, while evolving payer landscapes and distribution shifts are influencing access and uptake. This executive summary consolidates the most salient clinical, commercial, and policy trends that are reshaping the shingles vaccine environment and highlights the implications for stakeholders across development, manufacturing, distribution, and patient care delivery.

In recent years, recombinant vaccine platforms have introduced higher-efficacy alternatives to older live-attenuated formulations, altering clinical recommendations and immunization pathways. At the same time, demographic pressures from aging populations and intensified focus on adult immunization programs are generating renewed attention among public health authorities and private payers. As a result, manufacturers, providers, and distributors are reassessing supply strategies, service delivery models, and communication approaches to maximize coverage and minimize preventable disease burden.

This introduction frames the report's subsequent analysis, which explores transformative shifts in the landscape, cumulative policy impacts, segmentation-driven demand drivers, regional nuances, competitive positioning, recommended actions for industry leaders, and the research methodology underpinning the findings. The intent is to present a coherent, decision-oriented narrative that supports strategic planning and operational execution in an increasingly complex environment.

Detailed exposition of the multi-dimensional disruptive forces altering shingles vaccine adoption, procurement approaches, and stakeholder expectations across health ecosystems

The shingles vaccine landscape is experiencing a set of transformative shifts that extend beyond product performance and into distribution, payer engagement, and patient expectations. Technological advances, including improved recombinant antigen platforms and adjuvant systems, have elevated efficacy benchmarks and altered clinical guidance, prompting health systems and clinicians to reevaluate adult immunization protocols. Concurrently, advances in cold-chain logistics and digital distribution channels are enabling broader access while introducing new considerations for inventory management and supplier selection.

Payer dynamics are shifting toward value-based procurement and performance-linked contracting, which is incentivizing manufacturers to demonstrate long-term clinical and economic benefits. This emphasis on outcome-oriented reimbursement is driving increased investment in real-world evidence generation and post-marketing surveillance. In parallel, regulatory authorities are refining approval and labeling pathways to better reflect age-stratified risk-benefit profiles, which in turn affects recommendations from national immunization technical advisory groups and clinical societies.

Patient expectations and provider workflows are also evolving. Older adults are increasingly informed about vaccine options and seek clear guidance on comparative efficacy and safety, while primary care settings and specialist clinics are integrating vaccination into routine chronic disease management visits. Finally, the growing role of digital pharmacies and e-commerce platforms in medication access is accelerating the adoption of novel distribution models, necessitating new governance around cold-chain assurance and adherence support. Together, these shifts are redefining competitive advantage and operational priorities across the ecosystem.

In-depth analysis of how tariff-driven trade dynamics are reshaping supply chain decisions, procurement resilience strategies, and commercial contracting approaches for shingles vaccines

Policy adjustments such as tariffs and trade measures can create downstream effects across pharmaceutical supply chains, and anticipated tariff actions in the United States in 2025 have prompted stakeholders to assess operational resiliency. Manufacturers and distributors are re-evaluating sourcing strategies for critical raw materials, adjuvants, and vials to mitigate exposure to increased import costs and potential customs-related delays. In response, procurement teams are diversifying supplier bases, accelerating qualification of regional manufacturers, and negotiating longer-term contracts with price protection clauses to preserve continuity of supply.

Logistics partners and cold-chain providers are also adapting to potential cost shifts by optimizing routing, consolidating shipments, and exploring nearshoring opportunities to reduce tariff-related risk. These operational adjustments may increase lead times for certain inputs while prompting investment in domestic fill-and-finish capacity and additional cold-storage infrastructure. Clinicians and health systems should expect potential variations in procurement cadence as supply planners prioritize allocations based on contractual commitments and anticipated demand.

From a commercial perspective, increased import duties can pressure pricing strategies, margin structures, and contracting approaches with payers and distributors. Manufacturers may pursue differentiated pricing across channels or seek to bundle services-such as adherence support or analytics-to sustain overall value propositions. Regulatory and policy stakeholders are likely to intensify collaboration to expedite approvals for alternative suppliers and to ensure that national immunization efforts remain resilient in the face of trade-driven disruptions. Overall, the cumulative effect underscores the importance of proactive supply chain governance, scenario-based planning, and strengthened public-private coordination.

Strategic segmentation-driven insights that decode how vaccine type, age cohorts, end users, distribution channels, and dosing formats interact to influence adoption and delivery

Segmentation of the shingles vaccine landscape illuminates how product, demographic, care setting, distribution patterns, and dosing regimens interact to shape adoption pathways and service delivery models. Based on vaccine type, the environment distinguishes between recombinant zoster vaccine formulations, which have influenced clinical guidelines through higher observed efficacy in older cohorts, and live-attenuated zoster vaccine options that retain relevance in specific clinical circumstances. Decision-makers evaluating product portfolios must consider these efficacy and safety differentials alongside storage and handling requirements that affect downstream logistics.

Based on age group, demand drivers and clinical priorities vary across those aged 50 to 59 years, 60 to 69 years, and those 70 years and above. Younger older adults often present opportunities for proactive preventive outreach and workplace-based vaccination programs, whereas patients aged 70 and above frequently require tailored messaging around comorbidity management and safety signals. Providers must therefore align clinical communications and outreach workflows to the age-stratified risk-benefit calculus in order to improve uptake across cohorts.

Based on end user, delivery pathways bifurcate between clinics and hospitals, with clinics further differentiated into community clinics and private clinics and hospitals further categorized into general hospitals and specialty hospitals. Community clinics often serve as primary access points for preventive care with strong ties to local public health initiatives, while private clinics frequently emphasize patient convenience and bundled preventive services. General hospitals manage large-scale procurement and account for inpatient vaccination needs, whereas specialty hospitals may target vaccination for high-risk patient populations undergoing specific therapies. Each end-user segment requires distinct engagement strategies related to inventory management, clinician education, and reimbursement navigation.

Based on distribution channel, access is facilitated through hospital pharmacies, online pharmacies, and retail pharmacies, with online pharmacies further consisting of digital pharmacies and e-commerce platforms and retail pharmacies including chain pharmacies and independent pharmacies. Hospital pharmacies play a central role in institutional procurement and cold-chain stewardship, while online channels enable convenience and direct-to-consumer fulfillment that must be supported by robust temperature control and authentication protocols. Chain retail pharmacies offer scale and standardized vaccination services, whereas independent pharmacies provide localized patient counseling and flexible scheduling. Channel strategies must therefore integrate service design, cold-chain verification, and digital engagement to ensure both accessibility and adherence.

Based on dosage, delivery considerations span multi-dose and single-dose presentations. Multi-dose presentations can improve supply efficiency in high-volume settings but require stringent cold-chain and multi-dose vial handling procedures, whereas single-dose presentations support point-of-care convenience and reduce wastage in lower-volume environments. Manufacturers and providers should weigh dosing format decisions against clinic throughput, storage constraints, and patient flow dynamics to optimize both clinical outcomes and operational performance.

Comparative regional perspectives that reveal how payer dynamics, infrastructure, and demographic pressures drive differentiated adoption and access strategies across global theaters

Regional dynamics shape both the operational realities and strategic imperatives for stakeholders across the shingles vaccine value chain. In the Americas, public and private payers are increasingly focused on adult immunization schedules and value demonstration, which has accelerated investments in community outreach and integrated care pathways to improve coverage among older adults. Health systems in major markets are leveraging electronic health records and immunization registries to close care gaps, while distribution networks emphasize refrigerated logistics and chain pharmacy partnerships to maximize access.

In Europe, Middle East & Africa, regulatory heterogeneity and variable health system maturity produce a mosaic of adoption scenarios. High-income countries within the region generally align their clinical guidance with emerging efficacy evidence, while middle- and lower-income countries prioritize cost-effective procurement and targeted risk-group immunization. Cold-chain infrastructure variability in certain markets underscores the importance of adaptable product formats and decentralized storage solutions. Cross-border procurement mechanisms and regional regulatory harmonization efforts are increasingly relevant for manufacturers considering supply commitments and pricing strategies.

In the Asia-Pacific region, demographic shifts and expanding healthcare infrastructure are driving heightened demand for adult immunization services. Many markets are scaling up primary care capability and digital health platforms that can facilitate vaccine awareness and appointment scheduling. Local manufacturing capacity and strategic partnerships are likewise being prioritized to enhance supply security and shorten lead times. Across these regional contexts, tailored commercialization models that account for payer structure, distribution maturity, and public health priorities will be essential to achieving sustainable adoption and programmatic impact.

Holistic competitive intelligence highlighting how clinical evidence, operational resilience, and strategic partnerships define leadership in the shingles vaccine landscape

Competitive positioning in the shingles vaccine arena now rests on an integrated set of capabilities that extend beyond clinical differentiation to include supply chain agility, evidence generation, and multi-channel commercial excellence. Leading organizations are investing in post-authorization studies and real-world evidence programs to substantiate long-term effectiveness and to support contracting discussions with payers and health systems. At the same time, operational excellence in cold-chain logistics, fill-and-finish capacity, and supplier diversification has become a strategic priority to mitigate tariff and trade-related risks.

Strategic alliances and manufacturing partnerships are increasingly common as companies seek to broaden geographic reach while containing capital expenditure. Collaborative approaches to distribution-combining hospital procurement networks with retail pharmacy programs and digital fulfillment-are enabling more seamless patient journeys. Marketing efforts are focusing on clear, age-tailored clinical messaging and on clinician-facing education to ensure that vaccine options are integrated into routine care for older adults. Additionally, firms that develop robust adherence and patient-support services are better positioned to demonstrate value to payers and providers under outcome-oriented contracting models.

Intellectual property stewardship, regulatory preparedness, and the capacity to scale commercial operations rapidly during periods of heightened demand further distinguish market leaders. Organizations that align clinical evidence, operational resilience, and stakeholder engagement are most likely to sustain competitive advantage in a dynamic landscape where product efficacy, distribution integrity, and payer alignment converge to determine adoption outcomes.

Action-oriented recommendations that align evidence generation, supply resilience, omnichannel distribution, and stakeholder collaboration to accelerate vaccine access and uptake

Industry leaders should prioritize a set of pragmatic, high-impact actions to navigate the evolving shingles vaccine environment and to capitalize on emerging opportunities. First, organizations must invest in granular real-world evidence generation that demonstrates comparative effectiveness across age bands and clinical subgroups, enabling more compelling value propositions in payer negotiations and clinician adoption discussions. Second, strengthening supply chain resilience through supplier diversification, regional manufacturing partnerships, and validated cold-chain contingency plans will reduce exposure to trade and tariff volatility.

Third, manufacturers and distributors should advance omnichannel distribution strategies that harmonize hospital procurement, retail pharmacy scale, and secure online fulfillment, while ensuring rigorous cold-chain verification and patient adherence support. Fourth, tailored engagement programs for different end users-community clinics, private clinics, general hospitals, and specialty hospitals-will improve uptake by aligning service delivery models and inventory management to specific operational needs. Fifth, commercial teams should develop flexible contracting frameworks and bundled service offerings that reflect payer preferences for outcomes and long-term value, thereby facilitating access in both public and private settings.

Finally, cross-sector collaboration with public health authorities, patient advocacy groups, and clinical societies will amplify outreach efforts and establish clearer adult immunization pathways. By combining evidence generation, operational readiness, channel optimization, and stakeholder alignment, industry leaders can enhance vaccine accessibility and deliver measurable public health impact.

Transparent mixed-methods research approach that integrates expert interviews, regulatory synthesis, and scenario analysis to produce actionable, validated insights for decision-makers

This analysis draws on a mixed-methods research approach designed to integrate primary stakeholder insights with rigorous secondary synthesis and validation. The core methodology combined in-depth interviews with clinical experts, procurement leaders, and distribution partners alongside structured data extraction from public regulatory communications, clinical literature, and policy statements. Interviews were conducted across a range of care settings and regions to capture the operational diversity influencing vaccine delivery and to triangulate emerging themes around adoption barriers and enablers.

Complementing qualitative insights, the research incorporated scenario-based supply chain analysis to assess resilience considerations under different trade and policy conditions. Key assumptions were tested through sensitivity checks and cross-validated with logistics and manufacturing specialists to ensure feasibility and practical relevance. The approach prioritized transparency of sources, explicit documentation of analytic steps, and iterative validation with subject-matter experts to reduce bias and increase applicability for decision-makers.

Ethical considerations were observed in all primary research activities, and data handling adhered to relevant confidentiality and privacy standards. Where applicable, clinical findings referenced peer-reviewed evidence and regulatory guidance to contextualize recommendations. The resulting synthesis emphasizes actionable intelligence and pragmatic pathways for implementation, intended to inform strategic planning rather than provide normative policy prescriptions.

Concise synthesis of strategic imperatives linking clinical advancement, supply resilience, segmentation nuance, and regional variation to operationalize vaccine access goals

In conclusion, the shingles vaccine landscape is at an inflection point where technological advances, demographic shifts, and evolving procurement paradigms intersect to create both challenges and opportunities for stakeholders across the value chain. Recombinant vaccine platforms and improved logistics solutions are raising clinical performance expectations and expanding the scope for broader adult immunization strategies, while tariff and trade dynamics demand more resilient supply chain architectures and adaptive commercial models.

Segmentation nuances across vaccine type, age cohorts, care settings, distribution channels, and dosing formats underscore the importance of tailored approaches that align product attributes with real-world delivery constraints. Regional differences further emphasize the need for customizable engagement models that consider payer structures, infrastructure maturity, and local clinical priorities. Competitive advantage will accrue to organizations that can combine robust evidence generation with operational excellence and flexible contracting to meet the needs of payers, providers, and patients.

Ultimately, proactive planning, strategic collaboration, and investment in both clinical and logistical capabilities will determine which stakeholders are best positioned to improve access and deliver measurable public health impact. This report is intended as a decision-oriented resource to guide such investments and to support evidence-based action across the shingles vaccine ecosystem.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Shingles Vaccine Market, by Vaccine Type

  • 8.1. Recombinant Zoster Vaccine
  • 8.2. Zoster Vaccine Live

9. Shingles Vaccine Market, by Dosage

  • 9.1. Multi Dose
  • 9.2. Single Dose

10. Shingles Vaccine Market, by Age Group

  • 10.1. 50 To 59 Years
  • 10.2. 60 To 69 Years
  • 10.3. 70 Years And Above

11. Shingles Vaccine Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
    • 11.2.1. Digital Pharmacies
    • 11.2.2. E-commerce Platforms
  • 11.3. Retail Pharmacies
    • 11.3.1. Chain Pharmacies
    • 11.3.2. Independent Pharmacies

12. Shingles Vaccine Market, by End User

  • 12.1. Clinics
    • 12.1.1. Community Clinics
    • 12.1.2. Private Clinics
  • 12.2. Hospitals
    • 12.2.1. General Hospitals
    • 12.2.2. Specialty Hospitals

13. Shingles Vaccine Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Shingles Vaccine Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Shingles Vaccine Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Shingles Vaccine Market

17. China Shingles Vaccine Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AIM Vaccine Co., Ltd.
  • 18.6. Bavarian Nordic A/S
  • 18.7. Beijing Institute of Biological Products Co., Ltd.
  • 18.8. Bharat Biotech International Limited
  • 18.9. Biological E. Limited
  • 18.10. CanSino Biologics Inc.
  • 18.11. CanSinoBIO
  • 18.12. Changchun BCHT Biotechnology Co., Ltd.
  • 18.13. Chengdu Institute of Biological Products Co., Ltd.
  • 18.14. Daiichi Sankyo Company, Limited
  • 18.15. Dynavax Technologies Corporation
  • 18.16. GeneOne Life Science
  • 18.17. GlaxoSmithKline plc
  • 18.18. Green Cross Corporation
  • 18.19. Jiangsu Recbio Technology Co., Ltd.
  • 18.20. Johnson & Johnson
  • 18.21. Merck & Co., Inc.
  • 18.22. Moderna, Inc.
  • 18.23. Serum Institute of India Pvt. Ltd.
  • 18.24. Sinovac Life Sciences Co., Ltd.
  • 18.25. SK chemicals
  • 18.26. Vaccitech plc
  • 18.27. Valneva SE
  • 18.28. Vaxart, Inc.
  • 18.29. Yuxi Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL SHINGLES VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL SHINGLES VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL SHINGLES VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT ZOSTER VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTER VACCINE LIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SHINGLES VACCINE MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 50 TO 59 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 60 TO 69 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SHINGLES VACCINE MARKET SIZE, BY 70 YEARS AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DIGITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SHINGLES VACCINE MARKET SIZE, BY E-COMMERCE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SHINGLES VACCINE MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COMMUNITY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRIVATE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GENERAL HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SPECIALTY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS SHINGLES VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 101. LATIN AMERICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL SHINGLES VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 163. GCC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. GCC SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 166. GCC SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. GCC SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. GCC SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 169. GCC SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 170. GCC SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GCC SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 172. GCC SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 183. BRICS SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 193. G7 SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. G7 SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 196. G7 SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. G7 SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. G7 SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 199. G7 SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 200. G7 SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. G7 SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 202. G7 SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 203. NATO SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 204. NATO SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. NATO SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. NATO SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. NATO SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 209. NATO SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 210. NATO SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. NATO SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 212. NATO SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA SHINGLES VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA SHINGLES VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA SHINGLES VACCINE MARKET SIZE, BY DOSAGE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA SHINGLES VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA SHINGLES VACCINE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA SHINGLES VACCINE MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA SHINGLES VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA SHINGLES VACCINE MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA SHINGLES VACCINE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)